Intelligent Bio Solutions Initiates Key Multi-Site Study for FDA Clearance of Drug Screening System

summarizeSummary

Intelligent Bio Solutions has initiated a multi-site study for FDA 510(k) clearance of its fingerprint drug screening system, a crucial step for U.S. market entry and addressing its 'going concern' status.

check_boxKey Events

• Multi-Site Study Initiated for FDA Submission

  The company has begun a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine.

• Validation of Real-World Performance

  The study will evaluate the system's accuracy when operated by intended end-users across multiple clinical sites, demonstrating its real-world performance by non-specialized personnel.

• Key Step Towards U.S. Market Clearance

  This user performance evaluation is a critical component of the FDA 510(k) submission, aiming to show the system's effectiveness in pre-employment and workplace screening environments.

• Timeline for Data Collection

  Enrollment and data collection for the study are expected to be completed by the end of July 2026, with results to be included in the FDA submission package.

auto_awesomeAnalysis

Intelligent Bio Solutions has commenced a multi-site Method Comparison Study, a critical step towards securing FDA 510(k) clearance for its Intelligent Fingerprinting Drug Screening System for codeine. This study is designed to validate the system's accuracy and ease of use by typical workplace personnel, which is essential for U.S. market entry. Given the company's recent 'going concern' warning, progress on regulatory approvals for its core product is highly important for its future viability and potential revenue generation.